Benjamin C. Blount
YOU?
Author Swipe
View article: Supplementary Figure S1 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES)
Supplementary Figure S1 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES) Open
Supplementary Figure S1. Chemical structures of five AAs. Analytes that were monitored for isomeric separation but not quantified are indicated with an asterisk.
View article: Supplementary Table S1 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES)
Supplementary Table S1 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES) Open
Supplementary Table S1: Details of USDA food codes and logic for apportioning dietary intake used in our analysis
View article: Supplementary Table S2 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES)
Supplementary Table S2 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES) Open
Supplementary Table S2: Sample-weighted multiple regression results with dietary categories for urinary 1AMN, 2AMN, 4ABP (n = 1,845) among participants who smoked cigarette exclusively and nonusers of tobacco products, 2013-2014 NHANES
View article: Novel biomarkers to assess mold exposure among children with Asthma
Novel biomarkers to assess mold exposure among children with Asthma Open
View article: Lung lipids associated with smoking and ECIG use in a cross-sectional study and clinical trial
Lung lipids associated with smoking and ECIG use in a cross-sectional study and clinical trial Open
Background While electronic cigarettes (ECIG) may have lower toxicant delivery than cigarettes, ECIG-liquids and aerosols still contain toxicants that can potentially disrupt lung lipid homeostasis. Methods Participants from two studies un…
View article: Forest terpenes and stress: Examining the associations of filtered vs. non-filtered air in a real-life natural environment
Forest terpenes and stress: Examining the associations of filtered vs. non-filtered air in a real-life natural environment Open
View article: Exposure to volatile organic compounds and chronic respiratory disease mortality, a case-cohort study
Exposure to volatile organic compounds and chronic respiratory disease mortality, a case-cohort study Open
Background Chronic respiratory diseases (CRDs) are the third leading cause of death worldwide. Data of the associations between specific volatile organic compounds (VOCs), a major component of air pollution and tobacco smoke, and subsequen…
View article: Exposure to Secondhand Cannabis Smoke Among Children
Exposure to Secondhand Cannabis Smoke Among Children Open
Importance The degree that in-home cannabis smoking can be detected in the urine of resident children is unclear. Objective Test association of in-home cannabis smoking with urinary cannabinoids in children living at home. Design, Setting,…
View article: Data from Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users—Results from Wave 1 PATH Study
Data from Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users—Results from Wave 1 PATH Study Open
Background:Former smokers who currently use e-cigarettes have lower concentrations of biomarkers of tobacco toxicant exposure than current smokers. It is unclear whether tobacco toxicant exposure reductions may lead to health risk reductio…
View article: Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Figure 1 shows the analytic sample flow chart.
View article: Supplemental Table 4 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 4 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 4 provides prevalence rates of any tobacco use using TNE-2 cut-points.
View article: Supplementary tables 1-7 from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014)
Supplementary tables 1-7 from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014) Open
Table S1. Urinary BOEs in PATH Study Wave 1. Table S2. Urinary BOEs of Nicotine Metabolites in PATH Study Wave 1. Table S3. Urinary BOEs of TSNAs in PATH Study Wave 1. Table S4. Urinary BOEs of PAHs in PATH Study Wave 1. Table S5. Urinary …
View article: Supplemental Figure 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Supplemental Figure 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
This flow diagram outlines exclusion criteria that led to our final analytic sample. All N s are unweighted. Abbreviations: P30D= past 30-days. *This is the reference category for the exclusive or polytobacco cigarette use groups. Addition…
View article: Supplemental Table 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Supplemental Table 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
This table provides Receiver Operating Curve (ROC) characteristics and optimal cut-point to distinguish past 30-day daily and non-daily cigarette users from non-users*, overall and by sex and race/ethnicity.
View article: Supplemental Table 5 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 5 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 6 provides Wave 1 and Wave 4 TNE-2 cut-points for any tobacco use.
View article: Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Data from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014)
Data from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014) Open
Background:Monitoring population-level toxicant exposures from smokeless tobacco (SLT) use is important for assessing population health risks due to product use. In this study, we assessed tobacco biomarkers of exposure (BOE) among SLT use…
View article: Data from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Data from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
Background:Determine the overall, sex-, and racially/ethnically-appropriate population-level cotinine and total nicotine equivalents (TNE-2, the molar sum of the two major nicotine metabolites) cut-points to distinguish tobacco users from …
View article: Supplemental Table 2 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 2 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 2 provides demographic and tobacco use characteristics of any tobacco users.
View article: Supplementary Materials and Methods from Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users—Results from Wave 1 PATH Study
Supplementary Materials and Methods from Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users—Results from Wave 1 PATH Study Open
Description of biomarker assays
View article: Supplemental Table 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Assessment of Serum Concentrations of Α-Pinene, Β-Pinene, and Limonene in the U.S. Population from the 2013–2014 National Health and Nutrition Examination Survey
Assessment of Serum Concentrations of Α-Pinene, Β-Pinene, and Limonene in the U.S. Population from the 2013–2014 National Health and Nutrition Examination Survey Open
View article: Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 4 provides prevalence rates of any tobacco use using TNE-2 cut-points.
View article: Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Supplementary Table S2 from Tobacco Smoke is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013-2014 National Health and Nutrition Examination Survey (NHANES)
Supplementary Table S2 from Tobacco Smoke is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013-2014 National Health and Nutrition Examination Survey (NHANES) Open
Supplementary Table S2: Sample-weighted multiple regression results with dietary categories for urinary 1AMN, 2AMN, 4ABP (n = 1,845) among participants who smoked cigarette exclusively and nonusers of tobacco products, 2013-2014 NHANES
View article: Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Figure 1 shows the analytic sample flow chart.